Full-Time

Associate Director

LBA

Posted on 8/23/2025

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

No salary listed

Columbia, MO, USA

In Person

Category
Biology & Biotech (4)
, , ,
Requirements
  • Ph.D. with 5+ years of relevant experience; or M.Sc. with 7+ years of relevant experience; or B.Sc. with 10+ years of relevant experience in bioanalysis or other pertinent laboratory-based qualifications in a CRO or Pharma.
  • Supervisory experience in a multidisciplinary environment is essential.
  • Previous work experience in a GLP regulated environment is required.
  • Good leadership and people skills, teamwork experience, demonstrated conflict handling and resolution ability.
  • Good achievement record in scientific research and technical development evidenced by research paper and conference presentation.
Responsibilities
  • Responsible for personnel management activities of assigned staff such as: scheduling projects, training and development, providing regular direction and feedback on performance, disciplinary actions, preparing and delivering annual performance and salary reviews.
  • Responsible for scientific review of driving documents and reports and raising any pertinent issues to Director and/or Senior Director.
  • Contribute to financial success in their areas of expertise, as demonstrated by revenue and GM targets and client satisfaction achieved.
  • Responsible for ensuring quality and regulatory requirements are met by scientific staff in their team and that any quality issues, KPI issues are promptly resolved.
  • Responsible for ensuring continued operational improvements for efficiency and cost control in their areas of expertise.
  • Provide Scientific support to assigned Principle Investigator(s) within the area of expertise and ensure project timelines are respected and any delays communicated in a prompt fashion to all key internal and external stakeholders; Recommends resource adjustment when required based on deliverable schedules.
  • Responsible for set up and implementation of training for technical and scientific LBA staff.
  • Responsible for improved efficiency initiatives in the laboratory, including scheduling assays, operations and improving workflows.
  • Review costing assessments and scheduling projects with business development and Operations.
  • Contributes to the growth and development of Altasciences ligand binding assay services, as well as participate in strategic planning; Responsible for working closely with other management members and serve as back-up when any of them is out of office.
  • Contribute in professional internal/external presentations, scientific out-reach, and conferences.
  • Respect Health and Safety standards in terms of personal protection, laboratory maintenance, and work procedures.
  • May act as the Test Site Management for applicable validation and sample analysis studies as well as method SOP approval.

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Biotech/pharma consolidation demand for single-vendor early-phase development solutions increases.
  • 3D tissue technology adoption reduces animal testing costs and accelerates regulatory approval timelines.
  • Geographic footprint and participant database enable rapid enrollment for mid-size biopharma sponsors.

What critics are saying

  • Novo Holdings divesting Altasciences signals poor financial performance and operational cutbacks.
  • Charles River aggressive pricing on integrated packages captures 20% mid-size biopharma contracts.
  • AI-driven preclinical platforms from Insilico Medicine displace traditional animal safety pharmacology testing.

What makes Altasciences unique

  • Integrated CRO/CDMO spanning preclinical safety testing through Phase IV bioanalysis and manufacturing.
  • 9 North American facilities with 500,000+ participant database conducting 285+ trials annually.
  • VoxCell partnership integrates 3D tissue technology for human-relevant preclinical testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Company News

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Postmedia Network
Mar 28th, 2025
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category

For 14 years, Outsourced Pharma's CDMO Leadership Awards have recognized the top-performing contract development and manufacturing organizations based on comprehensive industry research, and feedback from sponsors.

BioSpace
May 29th, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities

Altasciences receives 2024 CRO Leadership Award for Capabilities.

INACTIVE